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Changes in Body Mass Index and Atherosclerotic Disease 
Risk Score After Switching From Tenofovir Disoproxil 
Fumarate to Tenofovir Alafenamide
Jason J. Schafer,1 Kaitlin N. Sassa,1 Jaclyn R. O’Connor,1 Ayako Shimada,2 Scott W. Keith,2 and Joseph A. DeSimone,3
1Department of Pharmacy Practice, Jefferson College of Pharmacy, Thomas Jefferson University, Philadelphia, Pennsylvania, USA, 2Sidney Kimmel Medical College, Division of Biostatistics, 
Thomas Jefferson University, Philadelphia, Pennsylvania, USA, 3Sidney Kimmel Medical College, Division of Infectious Diseases, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Background. Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF)-containing antiretroviral 
therapy (ART) can improve renal function and bone mineral density in people with human immunodeficiency virus (PWH). The 
switch can also negatively influence cholesterol, but changes in body mass index (BMI) and atherosclerotic cardiovascular disease 
(ASCVD) risk are unknown.
Methods. This retrospective observational study evaluated BMI and ASCVD risk score changes in virologically suppressed 
PWH who switched from TDF to TAF without switching other ART regimen components. Adults on TDF for ≥1 year with 2 
consecutive HIV ribonucleic acid values <200 copies/mL before a TAF switch were included. Body weight, BMI, cholesterol, 
and ASCVD risk score were collected for the year before and after the switch. Pre- and postswitch values were compared with 
the Wilcoxon signed-rank test. Changes in BMI and ASCVD scores were modeled using generalized estimating equations 
regression.
Results. One hundred ten patients were included. In unadjusted analyses, there were significant increases in weight, BMI, total 
cholesterol, LDL, HDL, and ASCVD risk score in the year after switching from TDF to TAF (each P ≤ .01). In regression models, 
switching from TDF to TAF was associated with a 0.45 kg/m2 increase in BMI (95% confidence interval [CI], 0.14–0.76) and a 13% 
increase in ASCVD risk score (95% CI, 4%–23%).
Conclusions. We observed significant BMI and ASCVD score increases in PWH 1 year after switching from TDF to TAF. The 
mechanism of changes is unclear and requires additional study.
Keywords:  BMI; cardiovascular disease risk; HIV; tenofovir alafenamide; weight gain.
Switching from tenofovir disoproxil fumarate (TDF) to 
tenofovir alafenamide (TAF)-containing antiretroviral therapy 
(ART) can maintain virologic efficacy, while preserving or 
improving renal function and bone mineral density in people 
with human immunodeficiency virus (PWH) [1–3]. The switch 
may also negatively influence cholesterol. Patients that switched 
to TAF-containing ART in clinical trials had significant in-
creases in total (Tchol) high-density lipoprotein (HDL-C) 
and low-density lipoprotein (LDL-C) cholesterol levels [3–5]. 
The impact of these changes on atherosclerotic cardiovascular 
disease (ASCVD) risk is unclear [6]. In addition, recent studies 
suggest that initiating TAF alongside an integrase inhibitor 
in treatment-naive patients or switching from TDF to TAF in 
treatment-experienced patients can lead to weight gain [7, 8]. 
Patients in the switch study often had changes in other ART 
regimen components, thereby confounding the ability to an-
alyze TAF alone [7]. The purpose of this study was to deter-
mine whether changes in weight, body mass index (BMI), and 
ASCVD risk score occur after switching from TDF to TAF, 
without switching other ART regimen components.
METHODS
This was a retrospective, observational study involving virally 
suppressed PWH who switched from TDF to TAF-containing 
ART between January 2016 and March 2018 at an urban, ac-
ademic medical center. Institutional review board approval 
was obtained before data collection. Adult patients on TDF-
containing ART for at least 1  year were included if they had 
evidence of persistent viral suppression. This was defined as 
having at least 2 consecutive human immunodeficiency virus 
(HIV) viral load values <200 copies/mL and no values >200 
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copies/mL in the year before the TAF switch. Patients were ex-
cluded if any other component of their ART regimen changed 
in the year before or after the TAF switch.
Demographic data including age, sex, and race were ex-
tracted from medical records of eligible patients along with 
preswitch CD4 cell counts, concomitant ART agents, duration 
of HIV infection, and total years on ART. Any non-ART medi-
cations prescribed for chronic use in the year after the TDF to 
TAF switch were also collected. Each non-ART medication was 
labeled as being associated with weight gain, weight loss, or no 
weight change according to package labeling.
To assess the study endpoints, body weight, BMI, Tchol, 
LDL-C, HDL-C, and triglyceride values were collected for the 
year before and after the switch. Pre- and postswitch median 
values for each of these parameters were then calculated.
To determine pre- and postswitch ASCVD risk scores, 
the 2018 American College of Cardiology/American Heart 
Association guidelines on treating blood cholesterol were used 
[6]. According to these guidelines, ASCVD scores can estimate 
the 10-year risk of a cardiovascular event in patients between 40 
and 75 years old. As a result, only patients between these ages 
with all other necessary data points to perform the ACSVD cal-
culation were assessed. Using age, sex, race, cholesterol, blood 
pressure, diabetes, and smoking status, ASCVD risk scores were 
generated for all eligible patients at the time of the ART switch 
and between 6 and 12 months thereafter for comparison.
Statistical Analysis
Patient demographics were summarized with counts and per-
centages for categorical variables and summarized with means 
and standard deviations or medians and interquartile ranges 
(IQRs) for numeric variables. Unadjusted distributions of the 
pre- and postswitch values for all study endpoints were sum-
marized with medians and IQRs and compared with Wilcoxon 
signed-rank tests. To further investigate the association of 
switching from TDF to TAF with BMI and ASCVD risk score, 
2 separate generalized estimating equation regression models 
were constructed. The covariates selected as candidates for each 
model included the following: a pre- versus post-TAF switch in-
dicator, age, sex, race, concomitant medications that can cause 
weight gain, concomitant medications that can cause weight 
loss, and time since HIV diagnosis. Two-way interactions with 
covariates and the pre- versus post-TAF indicator were also as-
sessed. Interaction and main effect terms were removed from 
the model one at a time using a hierarchical variable selection 
procedure (ie, never removing a main term that is part of an 
interaction term in the model) with a final retention criterion 
of 0.05. The ASCVD risk scores were highly right-skewed, so 
those data were log-transformed before modeling. All the ana-
lyses and visualizations were performed and created with SAS 
9.4 (SAS Institute Inc., Cary, NC). The significance level of each 
test was α = 0.05.
RESULTS
A total of 110 patients met study criteria and were included in the 
analysis (Table 1). The majority were African American (58.2%) 
and male (72.7%) with a mean age of 50 years old. Patients had 
been living with HIV and receiving ART for a median of 12 and 
8 years, respectively, with persistent viral suppression and im-
munologic recovery in response to ART. Approximately half of 
the patients were receiving integrase inhibitor-based regimens 
before their TAF switch.
The majority of subjects (65.5%) were either overweight or 
obese at the time they switched to TAF. The median patient 
weight was more than 185 pounds with a BMI of 28 kg/m2. In 
the year after their switch to TAF, patients had significant unad-
justed increases in both weight and BMI. On average, patients 
gained 3 pounds and their BMI increased by 0.5 kg/m2 (each 
P ≤ .01) (Table 2). In the regression model for BMI, only sex was 
retained as a covariate. The results of the model were consistent 
with the unadjusted analysis, suggesting that switching from 
TDF to TAF was associated with a 0.45 kg/m2 mean increase in 
BMI (95% confidence interval [CI], 0.14–0.76).
Unadjusted analyses also showed significant increases in 
Tchol, LDL-C, and HDL-C in the year after patients switched 
from TDF to TAF (each P ≤  .01) (Table 2). It is notable that, 
although the total cholesterol to HDL-C ratio did not change 
significantly after the switch, significant changes in ASCVD risk 
scores were observed. A total of 91 of 110 patients were between 
the ages of 40 and 75 and were eligible for ASCVD score cal-
culations. Of these, 68 had all other data necessary to perform 
the calculations both before and after the switch. For these pa-
tients, the median ASCVD score rose from 6.9% to 8.1% after 
switching to TAF (P < .01). Our regression model, adjusting for 
age, sex, race, concomitant medications that can cause weight 
gain, and time with HIV, suggested that switching from TDF to 
TAF was associated with a 13% average increase in ASCVD risk 
score (95% CI, 4%–23%).
DISCUSSION
We observed significant increases in both BMI and ASCVD risk 
in PWH who switched from TDF to TAF without changing any 
other ART regimen components. Importantly, patients in these 
analyses had longstanding HIV infection that was persistently 
controlled by ART. Patients were also at or above a normal BMI 
when switching to TAF. Therefore, it is unlikely that the weight 
gain patients experienced in this study represented a return to 
health, which commonly occurs after individuals initiate ART 
for the first time [9, 10].
In patients with advanced HIV who are underweight before 
starting ART, weight gain can prolong survival [11, 12]. In con-
trast, being overweight when initiating treatment or becoming 
obese on ART can increase a patient’s risk for dyslipidemia, dia-
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This is concerning because obesity is becoming increasingly 
prevalent in PWH, and these individuals already carry a dispro-
portionate risk for CVD [16–18]. More than half of the patients 
in this analysis were overweight or obese at baseline and expe-
rienced modest increases in BMI 1 year after switching to TAF. 
Importantly even modest increases in BMI may be clinically 
relevant. In a recent analysis of over 9000 PWH enrolled in the 
Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) 
study, the risk of diabetes and CVD increased by approximately 
20% per unit of BMI gained in the year after starting ART 
[13]. The extent to which the BMI changes we observed after 
switching ART could influence a patient’s risk of developing di-
abetes or CVD is unclear.
In terms of dyslipidemia, we observed significant increases 
in Tchol, LDL-C, and HDL-C in our patients after switching 
to TAF. These findings are consistent with observations from 
clinical trials. Also consistent with previous trials, we did not 
observe changes in Tchol/HDL-C ratios. Current guidelines on 
treating blood cholesterol recommend calculating an ASCVD 
risk score using cholesterol data in addition to a person’s age, 
sex, race, blood pressure, and smoking status [6]. When per-
forming this assessment for our patients, we observed a 13% 
increase in ASCVD risk scores after switching to TAF. This re-
sulted in many patients becoming eligible for treatment with a 
statin medication for ASCVD risk reduction. More specifically, 
before TAF, the median ASCVD risk score in our sample was 
6.9%, indicating that over half (53.3%) of the sample was below 
the threshold of 7.5% to meet statin eligibility criterion. After 
switching to TAF, the average 13% increase in ASCVD risk 
scores shifted 50.7% of our sample over the 7.5% statin crite-
rion. Taken together with the increases in BMI and cholesterol, 
the changes in ASCVD risk score may indicate an increased risk 
for CVD in PWH after switching from TDF to TAF.
This study has several limitations. First, as an observational 
study, the results cannot establish causal relationships between 
TAF and increases in BMI or ASCVD risk. Second, as a ret-
rospective chart review, we relied on the accuracy and com-
pleteness of medical records, but omissions or inaccuracies that 
influenced the results were possible. In addition, although we 
made every attempt to control for confounding variables with 
restrictive inclusion criteria and statistical analyses, it remains 
possible that data not measured or collected could have influ-
enced our results. For example, we were unable to collect data 
on patients’ caloric intake and physical activity. Finally, our co-
hort was predominantly African American and male from a 
single academic center in the Northeastern United States. As 
a result, the findings may not be generalizable to other popula-
tions. Given these limitations, additional investigations will be 
necessary to determine whether there are causal relationships 
Table 1. Demographics and Other Patient Characteristics Summary
Characteristic All Patients (n = 110)
Age, mean (SD) 50 (11.7)
Sex, n (%)  
Male 80 (72.7)
Female 30 (27.3)
Race, n (%)  




Years since HIV diagnosis, median (IQR) 12.0 (11.0)
Years on ART, median (IQR) 8.0 (8.0)
Preswitch CD4 count (cell/mm3), median (IQR) 627.5 (381.0)
Preswitch BMI category, n (%)  
Underweight 4 (3.6)
Normal weight 34 (30.9)
Overweight 31 (28.2)
Obese 41 (37.3)
Other ART agent, n (%)  
Integrase inhibitor 54 (49.1)
Protease inhibitor 18 (16.4)
Nonnucleoside reverse-transcriptase inhibitor 32 (29.1)
Other 6 (5.4)
Concomitant medication cause weight gain, n (%) 34 (30.9)
Concomitant medication cause weight loss, n (%) 29 (26.4)
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; HIV, human immunodefi-
ciency virus; IQR, interquartile range; SD, standard deviation.
Table 2. Unadjusted Outcomes Summary
Outcome Variable
Preswitch 
(TDF) Postswitch (TAF) Change (Post–Pre) P Value
Weight (lbs), median (IQR) 185.4 (55.8) 190.5 (60.5) 3.0 (9.2) <.01
BMI (kg/m2), median (IQR) 28.0 (10.8) 28.2 (10.0) 0.5 (1.4) <.01
Total cholesterol, median (IQR) 173.8 (44.0) 195.0 (42.0) 12.5 (32.3) <.01
LDL cholesterol, median (IQR) 98.6 (40.2) 112.1 (46.6) 8.2 (21.0) <.01
HDL cholesterol, median (IQR) 51.0 (19.0) 55.8 (24.0) 3.0 (12.0) <.01
Total to HDL cholesterol ratio, median (IQR) 3.5 (1.6) 3.5 (1.7) 0.1 (0.6) .25
Triglyceride levels, median (IQR) 103.5 (68.0) 109.5 (93.0) 4.0 (64.0) .28
Atherosclerotic CVD risk score, median (IQR) 6.9 (8.1) 8.1 (10.9) 0.4 (1.9) <.01
Creatinine clearance, median (IQR) 104.0 (38.0) 102.5 (42.0) −1.0 (17.0) .82
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between TAF exposure and increases in BMI or ASCVD risk. If 
relationships do exist, the associated mechanisms and any addi-
tional risk factors should be determined to optimize treatment 
for all PWH.
CONCLUSIONS
We observed significant increases in BMI and ASCVD risk in 
PWH 1 year after a switch from TDF to TAF without changes in 
other ART regimen components. The mechanisms associated with 
these metabolic changes are unclear and require additional study.
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